Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
Rhea-AI Summary
Climb Bio (Nasdaq: CLYM) will host an R&D Spotlight webcast on May 5, 2026 at 8:00 a.m. ET focused on budoprutug, an anti-CD19 monoclonal antibody for B-cell mediated diseases. The event will cover target rationale, clinical study design, dose selection, and development strategy.
Speakers include Climb Bio management and David Jayne, MD, Professor of Clinical Autoimmunity at the University of Cambridge. A replay will be available on the company's investor website about two hours after the live webcast and archived for at least 30 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – CLYM
On the day this news was published, CLYM gained 3.35%, reflecting a moderate positive market reaction. Argus tracked a peak move of +10.1% during that session. Our momentum scanner triggered 34 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $13M to the company's valuation, bringing the market cap to $389.31M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
CLYM is up 1.93% with mixed peer moves: CABA (+2.33%), KYTX (+4.01%), GLSI (+0.49%), VTYX (+0.07%), while AARD is down (-1.70%). No peers are in the momentum scanner and no same-day peer news is reported, suggesting a stock-specific move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Earnings update | Positive | +1.5% | Q4 and 2025 results with cash runway into 2028 and trial updates. |
| Feb 05 | Investor conferences | Positive | -7.9% | Announcement of three upcoming investor conference presentations and webcasts. |
| Jan 08 | Pipeline progress | Positive | +9.1% | Detailed 2026 strategic priorities and progress across budoprutug and CLYM116. |
| Nov 25 | Inducement grant | Neutral | +2.3% | Single employee stock option grant under Nasdaq inducement rule 5635(c)(4). |
| Nov 06 | Earnings update | Positive | +1.6% | Q3 2025 results with strong cash position and advancing clinical programs. |
Recent news has generally seen modest positive price reactions, with a notable selloff on an investor-conference announcement.
Over the last several months, Climb Bio has reported earnings, pipeline progress, and corporate updates. On Nov 06, 2025 and Mar 05, 2026, earnings reports highlighted cash runway into 2027–2028 and advancing budoprutug and CLYM116 trials, with small positive moves. A Jan 08, 2026 pipeline update, including multiple trials and site activations, coincided with a 9.05% gain. An investor-conference announcement on Feb 05, 2026 saw a -7.92% reaction. Today’s R&D webcast news continues the focus on budoprutug and CD19 in immune-mediated diseases.
Market Pulse Summary
This announcement highlights an upcoming R&D Spotlight webcast on May 5, 2026 focused on budoprutug and the CD19 opportunity in pMN, ITP, and SLE. It reinforces earlier disclosures that multiple budoprutug trials are active, including an SC formulation with dosing completed. Prior filings and updates emphasized cash runway into 2028 and advancing CLYM116. Investors may watch for new clinical details, dose rationale, and development strategy signals from this focused event.
Key Terms
cd19 medical
monoclonal antibody medical
subcutaneous medical
primary membranous nephropathy medical
immune thrombocytopenia medical
systemic lupus erythematosus medical
b-cell mediated medical
AI-generated analysis. Not financial advice.
WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&D Spotlight Series - a budoprutug webcast event, which is set for Tuesday, May 5, 2026, at 8:00 a.m. ET.
The event will highlight the Company’s budoprutug program, a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Budoprutug is being evaluated in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). Additionally, a clinical trial evaluating a subcutaneous (SC) formulation of budoprutug in healthy volunteers recently completed dosing.
Climb Bio’s management team will be joined by David Jayne, MD, Professor of Clinical Autoimmunity at the University of Cambridge and Director of the Vasculitis and Lupus Service at Addenbrooke’s Hospital.
The budoprutug event will feature:
- An overview of CD19 as a target for B-cell mediated disease
- Scientific rationale and potential commercial opportunity for budoprutug in pMN, ITP, and SLE
- Design of ongoing studies and dose selection
- Details on the Company’s development strategy for budoprutug
Webcast Information
The live webcast will be accessible via the “News & Events” section of the Climb Bio website: https://ir.climbbio.com/. A webcast replay will be available on the Climb Bio website beginning approximately two hours after the webcast event and will be archived for at least 30 days.
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy. For more information, please visit climbbio.com.
About Budoprutug
Budoprutug is a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Designed with enhanced effector function and low picomolar affinity, budoprutug targets and depletes CD19-expressing B cells, including plasmablasts and certain plasma cells, key sources of pathogenic autoantibodies. Early clinical data suggest budoprutug may offer durable B-cell depletion, rapid reductions in autoantibodies, and clinical remission in primary membranous nephropathy (pMN). Budoprutug is being evaluated in clinical trials for pMN, immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). A subcutaneous formulation is also in development to enable broader patient access. Budoprutug has been granted Orphan Drug Designation and Fast Track Designation by the FDA for the treatment of pMN.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefits, clinical potential and clinical development of budoprutug; plans for the development strategy for budoprutug; potential commercial opportunity for budoprutug in primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus; the sufficiency of Climb Bio’s cash resources for the period anticipated; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “suggest,” “target,” “would,” “will,” “working” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. Climb Bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of Climb Bio to timely and successfully achieve or recognize the anticipated benefits of its acquisition of Tenet Medicines, Inc. and its license agreement with Mabworks; changes in applicable laws or regulation; the possibility that Climb Bio may be adversely affected by other economic, business and/or competitive factors; Climb Bio’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates Climb Bio may develop. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Climb Bio’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in Climb Bio’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Climb Bio’s views as of the date hereof and should not be relied upon as representing Climb Bio’s views as of any date subsequent to the date hereof. Climb Bio anticipates that subsequent events and developments will cause Climb Bio’s views to change. However, while Climb Bio may elect to update these forward-looking statements at some point in the future, Climb Bio specifically disclaims any obligation to do so, except as required by law.
Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
